There is currently a lot of talk about how artificial intelligence (AI) may be able to reduce the burden of case processing while improving compliance and reducing processing costs. We asked 100 decision-makers in the pharmacovigilance space where in the adoption curve of new technologies they see their organization with respect to AI in pharmacovigilance. Over half of respondents consider their companies to be at least in the Early Majority with respect to adopting the use of artificial intelligence in pharmacovigilance.

Originally published in Life Science Leader.

View File